First-Line Treatment of Mycosis Fungoides at Clinical Stage IA, IB, or IIA (Early-Stage Disease)

This protocol applies to patients with mycosis fungoides (MF) presenting at clinical stage IA, IB, or IIA — collectively termed early-stage disease. The approach is shaped by evidence from comparative studies, including a meta-analysis of seven studies with 778 patients with histologically confirmed early-stage MF at these stages.

Clinical Scenario

The patient has mycosis fungoides confirmed at clinical stage IA, IB, or IIA. This staging delineates the extent of skin involvement and determines eligibility for the first-line treatment pathway outlined in this protocol.

First-Line Approach

Skin-directed therapies are recommended first-line for early-stage MF. The protocol recognises several options as clinically equivalent, with the preferred choice guided by stage and individual patient circumstances. The complete set of modalities, their indications, and the evidence supporting each is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ejca.2023.113343

Skin-directed therapies (SDT) are recommended first-line in early stages of MF but may also be used in combination with systemic options in advanced stages to control symptoms and improve skin tumour burden.
A recent review and meta-analysis by Phan et al. compared efficacy and adverse effects of PUVA and nbUVB including seven studies with a total of 778 patients with histologically confirmed early-stage MF, defined as stages IA, IB and IIA.

View source ↗